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An economic evaluation has been performed, analyzing
direct medical costs for the treatment of perennial allergic
rhinitis (PAR) with budesonide aqueous nasal spray and
fluticasone propionate nasal spray in Canada.
BACKGROUND: In this study, 314 patients, with at
least a 1-year history of PAR, were randomized into a
double-blind, parallel group study of 6 weeks duration.
The treatments were budesonide 256 g, fluticasone pro-
pionate 200 g, or placebo. Budesonide was significantly
more effective than fluticasone in reducing “blocked
nose.” Both active treatments produced significantly lower
mean scores for overall nasal symptoms compared with
placebo, and both were well tolerated. 
METHOD: A cost-minimization analysis, utilizing the clin-
ical trial data, was performed of the total costs of 1) budes-
onide-based and 2) fluticasone-based treatment strategies,
including the relative importance of the drug cost in both
strategies. 
RESULTS: In Canada, the average treatment cost per pa-
tient over 12 months in the budesonide group was CAN$
389.85 which was 23.3% lower than in the fluticasone
group, CAN$ 508.06, due to lower drug acquisition
costs. Drug costs represented between 24.6% and 42.1%
of total treatment costs for the budesonide and the fluti-
casone group, respectively. 
CONCLUSION: Budesonide aqueous nasal spray is a
cost-effective strategy in the treatment of perennial aller-
gic rhinitis.
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OBJECTIVE: The purpose of this study was to determine
the cost-effectiveness of erythropoietin against transfu-
sion in HIV patients treated with zidovudine from the so-
cietal perspective. 
METHOD: Cost-effectiveness was measured based on
probability of response to dose. The cost of drug with
and without the patient drug expenditure cap under the
Manufacturers’ Patient Assistance Program was consid-
ered. Measured were incremental cost per unit of blood
spared and incremental cost per QALY. Sensitivity analy-
sis was performed on all variables in the base case. 
RESULTS: Without the drug expenditure cap, the incre-
mental cost per unit of blood spared was $577.93
($160.34 with the cap). The incremental cost per QALY
without the cap was $118,620.13 and $32,909.71 with
the cap. The cost per unit of blood with the cap was 28%
below the cost of a unit of blood (PRBC). The break-even
cost of the drug was 77% below the current cost. A plot
of the cap against the cost per unit of blood spared
yielded a straight line. The cost per unit of blood spared
became zero at $4363.25 and became equal to the cost of
a unit of blood at $10,145. 
CONCLUSION: With the cost cap, erythropoietin can
be justified by incremental cost per QALY and on its
blood sparing and cost saving effects. The drug is most
cost-effective when it obviates the need for transfusion
entirely while it cannot be justified in patients who would
otherwise require 3 units of blood or less per month.
Variations in the cost of transfused blood units impact
cost-effectiveness but remain within acceptable limits for
typically cited values.
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It is possible with highly active antiretroviral therapy
(HAART) to retard progression from the HIV positive
state to AIDS. In developing an economic model of
HAART, annual costs associated with managing HIV
positive or symptomatic patients, and those with AIDS
were estimated. This presentation will focus on one as-
pect of this complex cost profile: the difference in the
management costs in a year where the AIDS patient sur-
vives versus the last year of life. 
OBJECTIVE: To estimate the difference in cost of AIDS
management between the last year of life and preceding
years. 
METHODS: Annual cost estimates include acute and sub-
acute inpatient care, outpatient care (excluding medica-
tions), emergency room, home care, hospice, counseling
and social services. Patient level data from the Massachu-
setts all payer discharge database allowed examination of
inpatient admissions for a cohort (n  340) of AIDS pa-
tients over 3 years (1994–1996). Patterns of inpatient care
for those discharged alive versus those who died in 1996
who also had admissions in 1994 and 1995 were con-
trasted. Additional 1996 data from 49,000 AIDS dis-
charges from six states were used to estimate inpatient
costs. These sources were supplemented by fee schedules,
other agency data and the literature. Costs are reported in
1998 US dollars, adjusted for medical inflation and cost-
to-charge ratios. 
RESULTS: The mean annual cost of acute inpatient care
is 36% higher in the last year of life ($31,302) than in
preceding years ($27,520). Inclusion of other resource
use increases the difference in management costs almost
three-fold ($18,289 versus $6,540). 
